Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
February 27 2020 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced the appointment
of life sciences industry executive Rohin Mhatre, Ph.D., to its
Board of Directors. Dr. Mhatre brings to the director role over 25
years of relevant experience, which includes his current position
as Senior Vice President, Product and Technology Development for
Biogen Inc., a leading multinational biopharmaceutical company. Dr.
Mhatre leads a cross-functional department responsible for product
and process development, process analytics and small-scale
manufacturing. Most recently, he has also led the Engineering and
Manufacturing Science departments. Throughout his career, he has
evaluated and implemented cutting-edge production platforms and
process analytical tools for a diverse array of therapeutics,
including monoclonal antibodies, gene therapies and
oligonucleotides, as well as small molecules. “We are delighted to
welcome Dr. Mhatre to our board,” said Karen A. Dawes, chairperson
of the board of Repligen. “The relevance of Rohin’s experience to
Repligen is clear. His skillsets and his passion for innovation
underscore his success in driving progress in biopharmaceutical
manufacturing, and we expect he will be a tremendous asset to the
company.” Tony J. Hunt, President and Chief Executive Officer said,
“Rohin understands first-hand the drivers to improve manufacturing
efficiency and yield, as biopharmaceutical manufacturing operations
move towards flexible, single-use solutions and the drug pipeline
diversifies beyond monoclonal antibodies. This will help us shape
the future strategic direction for Repligen as we expand our
products and applications." Dr. Mhatre joined Biogen Inc. in 1996
and has held numerous roles of increasing responsibility leading to
his current position of Senior Vice President, Product and
Technology Development. Dr. Mhatre’s previous roles with Biogen
include Vice President of Biopharmaceutical Development, where he
led a 300-member team with responsibility for cell line, cell
culture, purification, formulation and device development. Earlier
in his career with Biogen, he was focused on building out
analytical development and technical services, and prior to Biogen,
he led the purification and applications group at Applied
Biosystems (formerly Perseptive Biosystems). He received a Ph.D. in
chemistry from Northeastern University.
About Repligen CorporationRepligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
increase efficiencies in the process of manufacturing biological
drugs. We are inspiring advances in bioprocessing for the customers
we serve; primarily biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, MA (USA), and we
have additional administrative and manufacturing operations in
Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund,
Sweden; Breda, The Netherlands and Ravensburg, Germany.
This press release may contain forward-looking statements within
the meaning of the federal securities laws. Investors are cautioned
that statements in this press release which are not strictly
historical statements including, without limitation, statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including risks discussed from time to time in our filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update any forward-looking statements, except as
required by law.
Repligen Contact: Sondra S. NewmanGlobal
Head of Investor Relations(781) 419-1881investors@repligen.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/69522875-e4ac-4066-b040-24e5008e2bb3
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024